MarketFriction

Glaxosmithkline Pharmaceuticals Ltd

NSE GLAXO · BSE 500660 · Pharmaceuticals
₹2,771.10 +0.06%
NSE close2026-10-01
52 week range2,088.10 - 3,120.70
Market cap₹47,159 Cr.
P/E44.8
Nifty 500Midcap 150 Price band 20% Delivery 56.2%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue from operations9578059308151,0119499748059801,041995938
Operating costs668587673584689658641554644670644643
EBITDA289218257231322292333251336371351296
EBITDA margin %30%27%28%28%32%31%34%31%34%36%35%31%
Depreciation & amortisation181718161719151617201316
Finance costs001000101111
Non-operating income28-13532363935414436503644
Pre-tax profit29965271249344308359279354400373322
Effective tax rate %27%30%28%27%27%25%27%27%27%26%26%26%
Profit after tax21846194182252230263205257296278237
Earnings per share (Rs)12.842.7011.4810.7614.9113.5715.5212.1015.2017.4516.4014.00
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue from operations2,8382,9082,8713,1283,2242,9263,2783,2523,4543,7493,8223,955
Operating costs2,3602,4892,3632,5272,5672,3272,5162,4472,5452,5702,5122,601
EBITDA4784205086016575987628049091,1791,3091,354
EBITDA margin %17%14%18%19%20%20%23%25%26%31%34%34%
Depreciation & amortisation252738498379686670676667
Finance costs000164222133
Non-operating income12511970131-26291,401103-21149166166
Pre-tax profit5785115406833065252,0938398161,2601,4061,449
Effective tax rate %35%34%35%35%70%32%19%27%28%26%26%
Profit after tax376337351445933581,6956115909281,0361,068
Earnings per share (Rs)22.2019.8820.7026.295.5021.14100.0436.0534.8354.7561.1563.05
Paid out as dividend %113%75%85%76%727%142%90%89%92%99%93%
10 Years5 Years3 YearsTTM1 YearLast Year
Revenue CAGR3%5%6%6%
Profit CAGR10%15%18%11%
Share price CAGR7%14%22%5%
Average return on equity33%48%43%46%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Net block (property, plant)123204258325432758387331330321284281
Capital work in progress1152686059231,003120133020141433
Investments06000003665188131,1181,392
Current & other assets2,9772,5772,1402,7002,4772,2572,7153,9072,4582,4082,6922,618
Total assets3,2163,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324
Share capital85858585169169169169169169169169
Reserves & surplus1,7442,0991,9221,9731,9701,6511,3092,4941,5721,6081,7822,098
Total debt322110352016191033
Other liabilities & provisions1,3848699951,8891,7711,3151,6021,9501,5701,7602,1472,023
Equity + liabilities3,2163,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating cash flow3381392344734094905788114845821,290903
Investing cash flow180499301-104-153-57418-4068089-46397
Free cash flow (after capex)175-69-246391663365362,3714515731,273870
Financing cash flow-497-638-511-307-358-428-696-524-1,543-562-769-737
Net change in cash21-02462-1026300-119-25129475563
Cash conversion (OCF / EBITDA) %93%72%94%133%101%103%121%122%93%92%116%93%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Return on capital employed %42%29%22%26%31%33%38%37%36%51%63%61%
Receivable days111621191411272322232826
Inventory days91156111147131135159144131144126124
Payable days749773149109100135156122171186154
Cash cycle (days)277560173646501131-4-31-4
Working capital days-48267-90-72-38-39-94-57-64-99-91
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoter group %75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
Foreign investors %2.50%2.93%3.48%4.02%4.36%4.50%4.52%4.89%4.79%4.63%4.62%4.79%
Domestic institutions %10.01%8.64%7.90%7.51%7.34%7.30%7.79%7.71%7.75%7.70%7.68%7.81%
Government %0.01%0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Retail & others %12.48%13.42%13.62%13.48%13.30%13.21%12.69%12.41%12.45%12.67%12.69%12.42%
Shareholder count1,15,2681,14,6631,18,9941,18,5151,19,2281,19,6251,21,8851,23,6291,22,9041,22,4601,21,7631,26,087

Fundamentals

Market value₹ 47,159 Cr.
Last price₹ 2,784
P/E (trailing)44.8
Book value / share₹ 134
Return on capital61.4 %
Return on equity45.6 %
Dividend yield2.05 %
Face value₹ 10.0
Revenue CAGR (TTM)6%
Profit CAGR (TTM)11%
Consolidated figures.
Valuation
Market capRs 46,944 Cr
Enterprise valueRs 45,586 Cr
P/E (TTM)43.95x
Price to book20.70x
Price to sales11.87x
EV / EBITDA30.00x
EV / EBIT31.38x
EV / sales11.53x
Price to cash flow51.97x
Earnings yield2.28%
Dividend yield2.06%
P/E, 3-year average48.61x
P/B, 3-year average20.20x
P/E, 5-year average39.85x
P/B, 5-year average16.82x
Profitability
Operating margin (excl. other income)34.26%
Operating margin (incl. other income)38.60%
EBITDA margin38.42%
Pre-tax margin36.65%
Net profit margin27.01%
Net margin, latest quarter25.27%
ROE49.11%
ROCE66.11%
ROA24.57%
ROE, 3-year average44.13%
ROCE, 3-year average59.76%
ROA, 3-year average21.97%
ROE, 5-year average48.39%
ROCE, 5-year average63.41%
ROA, 5-year average25.00%
ROIC (approx.)117.67%
Tax rate26.32%
Other income / net worth7.32%
Growth
Sales growth (latest year)1.93%
Profit growth (latest year)11.69%
Sales CAGR, 3 years5.53%
Sales CAGR, 5 years5.49%
Profit CAGR, 3 years19.26%
Profit CAGR, 5 years23.67%
Sales growth QoQ-5.71%
Profit growth QoQ-14.64%
Sales growth YoY (latest quarter)16.55%
Profit growth YoY (latest quarter)15.69%
Per share
EPS (TTM)Rs 63.05
EPS (latest year)Rs 61.15
EPS (latest quarter)Rs 14.00
EPS, 3-year averageRs 50.24
EPS, 5-year averageRs 57.36
Book value per shareRs 133.85
Sales per shareRs 233.46
Cash flow per shareRs 53.32
Dividend per share (latest year)Rs 57.00
Dividend per share, 3-year averageRs 47.67
Dividend per share, 5-year averageRs 53.00
Dividends
Dividend payout93.21%
Dividend payout, 3-year average94.57%
Dividend payout, 5-year average92.49%
Efficiency
Asset turnover0.88x
Fixed asset turnover13.61x
Inventory turnover3.24x
Inventory days113 days
Debtor days26 days
Debtors turnover13.99x
Leverage
Total debtRs 33 Cr
Cash and bankRs 1,391 Cr
Net debtRs -1,358 Cr
Debt to equity0.01x
Net debt / EBITDA-0.89x
Interest coverage442.91x
Current ratio (filing 2026-03-31)2.13x
Quick ratio (filing 2026-03-31)1.87x
Trade payables (filing 2026-03-31)Rs 570 Cr
Owners' fund to total sources52.44%
Debt to assets0.77%
Cash flow
Operating cash flow (latest year)Rs 903 Cr
Investing cash flow (latest year)Rs 397 Cr
Financing cash flow (latest year)Rs -737 Cr
Net change in cash (latest year)Rs 563 Cr
Sales to cash flow4.23x
Statement figures
Net sales (TTM)Rs 3,955 Cr
Net sales (latest year)Rs 3,822 Cr
Sales (latest quarter)Rs 938 Cr
Operating profit excl. other income (latest year)Rs 1,309 Cr
Operating profit (latest quarter)Rs 296 Cr
Other income (TTM)Rs 166 Cr
EBITDA (TTM)Rs 1,520 Cr
PBDT (TTM)Rs 1,516 Cr
Profit before tax (TTM)Rs 1,449 Cr
Tax (latest year)Rs 370 Cr
Net profit (TTM)Rs 1,068 Cr
Net profit (latest year)Rs 1,036 Cr
Net profit (latest quarter)Rs 237 Cr
Depreciation (TTM)Rs 67 Cr
Depreciation (latest quarter)Rs 16 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 1,483 Cr
Total expenditure (latest year)Rs 2,512 Cr
Total income (latest year)Rs 3,988 Cr
Share capitalRs 169 Cr
ReservesRs 2,098 Cr
Shareholders' fundsRs 2,267 Cr
Total assetsRs 4,324 Cr
Net blockRs 281 Cr
Capital work in progressRs 33 Cr
InvestmentsRs 1,392 Cr
ReceivablesRs 273 Cr
InventoryRs 458 Cr
Other liabilitiesRs 2,023 Cr
Shares outstanding (crore)16.94
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 44.0 is at the 23th percentile of its own 9.4-year range (median 61.1, low 12.4, high 295.2).
P/B 20.70 is at the 78th percentile (median 13.86).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodGLAXONifty 50Difference
1 week-2.1%-2.8% +0.7 pts
1 month-7.5%-6.8% -0.7 pts
3 months+15.7%-7.6% +23.3 pts
6 months+21.4%+0.4% +21.0 pts
1 year+1.2%-9.9% +11.1 pts
2 years+1.7%-13.6% +15.2 pts
3 years+79.0%+14.2% +64.8 pts
5 years+88.6%+27.9% +60.7 pts
117 mutual fund schemes hold about ₹3,278 Cr. Over three months 53 bought more and 10 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
SBI Midcap Fund1.47%360 +4%
SBI Midcap Fund1.47%358 +4%
Kotak Large & Mid Cap Fund1.04%336 +4%
Nippon India Pharma Fund3.31%314 +16%
Quant Mid Cap Fund2.93%236 +100%
Nippon India Growth Mid Cap Fund0.33%170 +1%
SBI Dividend Yield Fund1.60%137 +7%
Bandhan Large & Mid Cap Fund0.51%106 +39%
Bajaj Finserv Flexi Cap Fund1.18%97 -3%
Bandhan ELSS-Tax Saver Fund1.20%84 +7%
Tata Aggressive Hybrid Fund1.87%76 -20%
Mahindra Manulife Small Cap Fund1.12%61 +266%
Aditya Birla SL MNC Fund1.75%58 +6%
Helios Mid Cap Fund2.30%51 +49%
Tata Business Cycle Fund1.97%51 +10%
Baroda BNP Paribas Mid Cap Fund1.76%47 +5%
Bajaj Finserv Multi Cap Fund2.84%46 +48%
Quant Healthcare Fund10.58%45 +349%
Tata India Pharma & Healthcare Fund2.72%42 -43%
Bandhan Multi Cap Fund1.19%37 +5%
Bajaj Finserv Balanced Advantage Fund2.75%35 +30%
Nippon India Multi Cap Fund0.05%30 +100%
Aditya Birla SL Multi-Cap Fund0.41%30 +0%
Kotak Manufacture in India Fund0.97%29 -3%
Bajaj Finserv Multi Asset Allocation Fund1.41%27 +2%

Red flags

F-score 5 of 8
lookRegulator order or action Regulator order or action 2026-08-06: GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2017-03-30GlaxoSmithKline Pte LtdPromotersother3,192,238Rs 869.88 CrInter-se-Transfer
2017-03-30Castleton Investment LtdPromoter Groupother3,192,238Rs 869.88 CrInter-se-Transfer
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹938 Cr +16.5% vs Jun 2025. Net profit ₹237 Cr +15.6%.
Against our estimate for Jun 2026: sales +10.0%, profit +2.6% in line. Our estimate for Sep 2026: sales Rs 1,072 Cr, profit Rs 290 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-05-29Dividend - Rs 57 Per Share
2025-05-30Dividend - Rs 42 Per Share
2024-11-07Interim Dividend - Rs 12 Per Share
2024-05-31Dividend - Rs 32 Per Share
2023-06-30Dividend - Rs 32 Per Share
2022-07-07Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share
2021-07-19 Annual General Meeting/Dividend - Rs 30 Per Share
2020-07-17 Dividend - Rs 20 And Special Dividend - Rs 20 Per Share
2019-07-11 Annual General Meeting/Dividend Rs 20 Per Share
2018-09-11 Bonus 1:10.5000
2018-07-13 Dividend- Rs 35 Per Share
2017-07-14 Dividend - Rs 30/- Per Share
2016-07-15 Dividend Rs 50/- Per Share
2015-07-23Annual General Meeting/Dividend - Rs 62..50/- Per Share
2014-04-03Final Dividend Rs.50/- Per Share
2013-04-04Dividend Rs. 50 Per Share
2012-03-29Dividend Rs.45/- Per Share
2011-03-14Dividend-Rs.40/- Per Share
2010-03-10Dividend-Rs.30/- Pr Share
2009-03-18Div Fin-Rs.22 + Spl-Rs.18
2008-04-02Div Fin-Rs18+Spl-18 Pr Sh
2007-03-14Div Fin-170% + Spl-140% Purpose Revised
2006-03-24Fin Div-Rs14+Spl Div-Rs14
DateTypeWhat it says
2026-09-15Shareholder meetingVoting results.
2026-09-02General UpdatesGeneral UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026
2026-09-02Shareholder meetingNotice of Postal Ballot
2026-08-19General UpdatesGeneral Updates
2026-08-13Shareholder meetingNotice of Postal Ballot
2026-08-06Concall / analyst meetTranscript
2026-08-06Regulatory actionAction(s) taken or orders passed
2026-08-05Concall / analyst meetLink of Recording
2026-08-03Concall / analyst meetLink of Recording
2026-08-03ResignationResignation of Director/KMP/SMP
2026-08-03Change in ManagementChange in Management
2026-08-03Director changeChange in Director(s) of the company.
2026-08-03CessationCessation of Subesh Wiliams as Non- Executive Director of the company w.e.f. August 03, 2026.
2026-08-03General UpdatesGeneral Updates
2026-08-03Press ReleaseA press release dated August 03, 2026, titled "Press Release".
2026-08-03Board meeting outcomeGlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-03Investor PresentationInvestor Presentation
2026-07-21Concall / analyst meetSchedule of meet
2026-06-30Shareholder meetingProceedings of Annual General Meeting held on Jun 30, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with vo...
2026-06-25Regulatory actionAction(s) taken or orders passed
2026-06-08UpdatesLetter for weblink for Annual Report .
2026-06-05General UpdatesBRSR Report
2026-06-05Shareholder meetingNotice of Annual General Meeting to be held on Jun 30, 2026
2026-05-29ResignationResignation of Director/KMP/SMP
2026-05-29CessationCessation of Dr Simrat Sohal as Other of the company w.e.f. August 05, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd (GLAXO) has a market capitalisation of Rs 47,159 Cr. at the 2026-10-01 close.

What is the P/E ratio of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd trades at a P/E of 44.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Glaxosmithkline Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Glaxosmithkline Pharmaceuticals Ltd sales was Rs 938 Cr (+16.5% vs Jun 2025) and net profit was Rs 237 Cr.

What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd?

The 52-week high is Rs 3,120.70 and the 52-week low is Rs 2,088.10.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03